Back to News & Events

CFB Announces New Bioentrepreneur & Executive-In-Residence

March 5, 2020

The Center for Biotechnology at Stony Brook University has announced the appointment of Dr. Mario R. Mendoza as Executive-In-Residence, and Dr. William Mann as its newest BioEntrepreneur-In-Residence (BEIR). Drs. Mendoza and Mann have extensive bioscience industry experience affording them unique perspectives in their respective roles in residence at the Center for Biotechnology (CFB). Each will work with the CFB and the Long Island Bioscience Hub (LIBH), a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health. Dr. Mann will identify commercially promising academic technologies that have the potential to support company formation while Dr. Mendoza will serve in an advisory capacity for bioscience startup companies in the hub.

Dr. Mario R Mendoza is a clinical anesthesiologist (practiced at the NIH) and currently a healthcare and pharmaceutical industry medical/medical affairs consultant with over 13 years of combined experience in patient clinical care, clinical development, R&D, medical affairs (Abbott, Pfizer and Centrexion Therapeutics), and FDA medical devices regulation. Dr. Mendoza earned his BS degree in chemistry from SUNY College at Old Westbury, and a MS in organic chemistry from the University of Illinois at Urbana-Champaign. He earned his M.D. from the University of Illinois at Chicago College of Medicine and then completed an FDA Commissioner’s Fellowship Program and stayed on at FDA as a Medical Officer/Medical Consultant.

Dr. William R. Mann is Principal of Lodestar Biopharma Solutions LLC, which assists clients in the development of R&D strategies for regulatory and commercial success, business development, and M&A. Previously, he was President and CEO at Helsinn Therapeutics (US), where he transformed the sixteen employee R&D start-up into a profitable commercial company with a team of over one hundred. At Sapphire Therapeutics, Dr. Mann facilitated an investor exit through M&A while managing the company’s lead clinical development program. He also held leadership positions at Novartis in R&D and business development. Dr. Mann holds a PhD in biochemistry from the University of Aberdeen, Scotland and an MBA from Rutgers University.
“We are excited to have Mario and Bill join us at the Center for Biotechnology. Their extensive and varied industry experiences are wonderful assets to our program. The further expansion of our BEIR Program allows us to continue to advance our agenda, fueling the developing bioscience industry in the region” Diane Fabel, Director of Operations at the Center for Biotechnology said.

“I’m thrilled to become an Executive-in-Residence for the Center for Biotechnology.” stated Dr. Mendoza “I’m greatly looking forward to getting involved with biotech industry innovators collaborating with the organization. I believe the bioscience community in the region is robust and the support and partnership with organizations like the Center for Biotechnology are critical in driving innovation in the biotech space, and in getting innovative patient-centric products to market for the benefit of the patient and healthcare provider communities.”

“The work of the Center for Biotechnology is incredibly important to the bioscience community in the region, and I’m eager to be joining the organization.” Dr. Mann stated. “The innovation potential within the region is immense, and I look forward to the collaborative opportunities that lie ahead.”

Dr. Mann will work to identify a technology or technologies from within LIBH partner institutions that will create the foundation for licensing and company formation. He will have the support of the Center for Biotechnology business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. Ultimately, the goal is to help the company position itself for SBIR/STTR grant opportunities, as well as Angel and VC investment. In his role as Executive-in-Residence, Dr. Mendoza will offer invaluable support to the CFB client company portfolio by providing guidance and expertise in diverse areas including, but not limited to, product development, intellectual property strategy, regulatory affairs, capital formation, medical affairs and reimbursement.

The addition of Drs. Mendoza and Mann marks ten entrepreneurs and two executives-in-residence working with the Center for Biotechnology under their BIER program. Collectively, the Center for Biotechnology BEIRS have launched twelve new companies since the program’s inception in 2013.

View PDF announcement. 

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 5065
                    [post_author] => 4
                    [post_date] => 2026-09-01 14:03:32
                    [post_date_gmt] => 2026-09-01 18:03:32
                    [post_content] => 

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.





BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.





Application deadline: October 29, 2026, 5:00pm ET





For info sessions, eligibility and deadlines visit our REACH Website and FAQ.





The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.





Questions? Reach out to our program contacts or sign up for office hours:





Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here





Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here












                    [post_title] => BioREACH: Translational Research Funding Opportunity
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => bioreach-translational-research-funding-opportunity
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2026-09-04 11:55:36
                    [post_modified_gmt] => 2026-09-04 15:55:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=5065
                    [menu_order] => 0
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 4437
                    [post_author] => 4
                    [post_date] => 2024-05-31 15:10:00
                    [post_date_gmt] => 2024-05-31 19:10:00
                    [post_content] => 






Congratulations to Dr. Carol A. Carter, SUNY Distinguished Professor in the Department of Microbiology and Immunology at the Stony Brook University Renaissance School of Medicine (RSOM), who was recently elected aa a member of the U.S. National Academy of Sciences (NAS. 





The NAS is made up of the country’s leading researchers, who are elected in recognition of their distinguished and continuing achievements in original research. Election is considered one of the highest honors that a scientist can receive.





Dr. Carter is best known as an early pioneer in HIV research. At the onset of the AIDS pandemic, she advanced understanding of the viral-encoded protease and purified the viral capsid protein for structural and biochemical studies. She has also conducted research on Epstein-Barr Virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus Virus-2 (SARS CoV-2), pathogens causing organ transplant rejection and COVID-19, respectively.





The Center for Biotechnology has had supported Dr. Carter's interests in exploring the potential commercial applications of her research through our NIH-REACH program and Long Island Bioscience Hub (LIBH). 





Read more about Dr. Carter's work and her recent nomination here. 


                    [post_title] => Dr. Carol A. Carter Elected to U.S. National Academy of Sciences
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => dr-carol-a-carter-elected-to-u-s-national-academy-of-sciences
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-09 15:10:32
                    [post_modified_gmt] => 2024-08-09 19:10:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=4437
                    [menu_order] => 0
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 3469
                    [post_author] => 3
                    [post_date] => 2020-05-05 08:25:54
                    [post_date_gmt] => 2020-05-05 08:25:54
                    [post_content] => *This list will be updated as opportunities arise. (Updated 7.21.20)

NIH & NIAD Limited Competition Emergency Awards: Shared PPPE Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies

The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”. Rolling deadline - details here: https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html#_Section_I._Funding



NIH & NIBIB Rapid Acceleration of Diagnostics (RADx) 

Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Learn more: https://www.poctrn.org/radx

Pfizer COVID-19 Competitive Grant Program 

Pfizer has released a Request for Proposals (RFP) to provide financial support for organizations producing independent educational programs and quality improvement initiatives designed to combat this evolving crisis. This competitive grant program from Pfizer Global Medical Grants (GMG) involves a publicly posted RFP that provides details regarding a specific area of interest, sets timelines for review and approval, and uses an internal review process to make final grant decisions. For this RFP, organizations are invited to submit an application addressing the gaps in knowledge and practice of COVID-19 management as outlined here.

Mozilla launches COVID-19 Solutions Fund

Mozilla has created a COVID-19 Solutions Fund as part of the Mozilla Open Source Support Program (MOSS). Through this fund, awards of up to $50,000 each will be provided to open source technology projects which are responding to the COVID-19 pandemic in some way.

As part of the COVID-19 Solutions Fund, applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation)will be accepted. More details here. Application here.

NYS COVID-19 Manufacturing Grants for Masks, Ventilators

The COVID-19 Manufacturing Grants, part of the Jeff Lawrence Innovation Fund, are designed to aid existing New York State small to medium-sized manufacturing companies that can meet prevailing FDA requirements and can quickly accelerate production of personal protective equipment and respiratory care equipment that has been depleted due to the COVID-19 outbreak. Full details here. (Deadline April 17, 2020)

NIBIB announces three COVID-19 Notices of Special Interest

Multiple Notices of Special Interest include administrative supplements and emergency competitive revisions funding for current grantees; SBIR/STTR opportunities; and investigator-initiated research opportunities. Current grantees and new applicants are encouraged to apply immediately. More here.

Fast Grants 

Fast Funding for COVID-19 Science. Scientist at academic institutions currently working on a COVID-19 related project and in need of funding are invited to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. More: fastgrants.org

NIH COVID-Specific Funding Opportunities (Update) 

Multiple Agency NOSI listed here.

National Institute of Allergy and Infectious Diseases: Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) RFA-AI-20-028

Administrative Supplements to Existing NIH Grants and Cooperative Agreements: Funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award. More.

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements: Funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner. More.

NSF Request for SBIR/STTR Phase I Proposals Addressing COVID-19

Phase I proposals should focus on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis. Areas of research include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. To apply, you must first develop and submit a Project Pitch at https://seedfund.nsf.gov/apply/. Assuming your pitch is approved, you will be invited by NSF to submit a grant application. More information here.

Department of Defense - Newton Award for Transformative Ideas during the COVID-19 Pandemic

This award will be presented to a single investigator or team of up to two investigators that develops a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. BRO-20-NEWTON (5/5/20 deadline)

COVID-19 Therapeutics Accelerator

Established by The Gates Foundation and Wellcome, this initiative aims to accelerate and evaluate new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The COVID-19 Therapeutics Accelerator will not be conducting a traditional funding call. To learn more about the funding process, or how to invest in the accelerator, contact epidemics@wellcome.ac.uk 

Small Business Assistance Programs

Stony Brook University Small Business Development Center is available to assist business owners trough the abundance of resources available for your particular business/industry and to avoid the most common mistake of incomplete or inaccurate Economic Injury Disaster Assistance Loan applications. Visit their website for more information.

Stony Brook University CEAS Student Opportunity: COVID-19 Innovation Teams

Stony Brook University's College of Engineering and Applied Sciences' Vertically Integrated Project Program is focusing special attention on the urgent needs of the COVID-19 pandemic. Learn more.

Innovate2Ventilate: The CoVent-19 Challenge

The CoVent-19 Challenge invites engineers, innovators, designers, and makers to produce rapidly deployable designs for mechanical ventilators. Launching on April 1, 2020, the deadline for the open-entry round of competition is May 1, 2020. Round 2 of the challenge is an invitation-only competition with a deadline of June 1, 2020. More: coventchallenge.com



COVID-19 Funding Opportunities - Summary via Stony Brook University Research 

The funding opportunities listed here are posted on the Pivot database, grants.gov, NIH Guide for Grants and Contracts, and nsf.gov. Detailed information on NIH funding opportunities and other guidance related to COVID-19 can be found here. Investigators should check eligibility and obtain any necessary approvals before applying.

Stony Brook University Faculty Funding Opportunity 

Stony Brook University Office of the Vice President for Research, together with the Institute for Engineering-Driven Medicine, announce this special initiative COVID-19 seed funding opportunity.

The purpose of this program is to seed research that has a direct connection to the current COVID-19 pandemic.Applications are due April 10. Details about eligibility, award amounts and application process can be found here.



Contacting New York State to offer your COVID-19 Resource: 

Businesses with capabilities relevant to needed medical equipment and supplies email to COVID19supplies@esd.ny.gov.

Businesses interested in selling products to the state should contact Simonida Subotic at 646-522-8477 or covid19supplies@exec.ny.gov.

Businesses interested in receiving state funding to manufacture PPE products should contact Eric Gertler at 212-803-3100 or COVID19supplies@esd.ny.gov.

Indie Bio Coronavirus Initiative 

Indie Bio is seeking up to 8 startups to receive a minimum of $250,000 each to pursue the development of diagnostics, therapeutics, vaccines, disinfection, and other solutions addressing the worldwide problem of emerging infectious diseases. More.

BARDA COVID-19 Funding Opportunities

BARDA BAA (no funding limit) 

Novel Coronavirus EZ-BAA (solicitations for funding up to $750K)

Research Foundation of SUNY COVID-19 Funding Opportunities 

**NEW**  SUNY Research Seed Grant Program RFP #20-03-COVID & Submission form.

Aggregate list of opportunities: https://www.rfsuny.org/about-us/covid-19/covid-19-funding/

Biotechnology Innovation Organization (BIO) Coronavirus Resources

Resource page includes Business Resource Center, Service Provider Directory and Coronoavirus Hub where companies can share what they need and how they can help.

CAD $200K ventilator design challenge for COVID-19 patients 

the Challenge is lead by Code Life.ca and the Montreal General Hospital foundations. The designs are due end of March 2020. The details and rules are posted there, and participants can sign up to begin: https://www.agorize.com/en/challenges/code-life-challenge/

OTHER CHALLENGES

Business Incubator Association of New York State - Innovate to Ventilate 

Hauppauge Industrial Association of Long Island (HIA-LI) Pivot to PPE

RESOURCES

COVID-19 Open Research Dataset (CORD-19)
Ginkgo commits $25M of free access to platform for partner COVID-19 projects

 
                    [post_title] => COVID-19 Funding and Resource Opportunities
                    [post_excerpt] => An aggregate list of COVID-19 related funding opportunities and technology and business related resources. This list will be updated as opportunities arise. 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => covid-19-resources
                    [to_ping] => 
                    [pinged] => 
https://indiebio.co/indiebio-covid-response/
                    [post_modified] => 2024-12-03 15:00:20
                    [post_modified_gmt] => 2024-12-03 20:00:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=3469
                    [menu_order] => 71
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 2689
                    [post_author] => 3
                    [post_date] => 2017-05-08 17:15:49
                    [post_date_gmt] => 2017-05-08 17:15:49
                    [post_content] => The Center for Biotechnology (CFB) at Stony Brook University is a New York State Center for Advanced Technology and the lead institution of the Long Island Bioscience Hub. The CFB provides the cross-institutional infrastructure for technology development, technology transfer, strategic industry partnerships, new company formation, attraction of investment capital, and other commercialization activities.

The CFB seeks ongoing technology and business development consulting services for its faculty and small business clients. The CFB works primarily with faculty and emerging small businesses to help them develop their technology and business strategy to prepare them for strategic partnerships and/or investment.

Consulting services anticipated, but not limited to:

    
 	
  • Conduct thorough due diligence on select technologies under consideration for investment by the CFB. Develop written assessments.
    • 
 	
  • Participate in in-person meetings on a weekly basis with faculty innovators and emerging companies to provide strategic guidance in intellectual property, competitive analysis, regulatory strategy, manufacturing, company formation and other issues related to commercialization strategies.
    • 
 	
  • Actively manage a project portfolio of funded technologies ensuring milestones are met and will add commercial value.
    • 
 	
  • Assist faculty in the development of applications for funding.
    • 
 	
  • Assist clients to develop effective fundraising strategies and materials.
    • 
 	
  • Participate in CFB technology and business development initiatives including the Boot Camp, Strategy Sessions, Long Island BioMentor Service and Life Sciences Summit.
    • 
 	
  • Help source and conduct due diligence on emerging company candidates for the Life Sciences Summit.
    • 
 	
  • Consult with CFB on specific technologies regarding commercialization and viability for moving forward. 
    • 
 	
  • Consult with CFB clients on milestones required for licensing, strategic partnerships, investment, and/or manufacturing.
    • 
 	
  • Consult with CFB staff on client work, intellectual property, as well as patent, regulatory, commercialization strategies as needed.
    • 
 	
  • Consult on course content for CFB programs such as the Innovation Boot Camp and Fundamentals course. Serve as instructor or guest lecturer as needed.
    • 
 	
  • Review, interpretation, and advice of patents, websites, articles related to specific technology. 
 Required Qualifications:
    • 
 	
  • Direct experience in the management of business and technical issues associated with advanced bio-based technology commercialization, including:

      
 	
    •  Due Diligence
      • 
 	
    •  IP Strategy
      • 
 	
    •  Fundraising
      • 
 	
    • Product development
      • 
 	
    •  Regulatory
      • 
 	
    • Manufacturing (preferred)
      • 
 	
    • Sales and Marketing (preferred)
      • 
 	
    •  Licensing
      • 

    

    • 
 	
  • Technology development experience in working with faculty-members and entrepreneurs seeking to commercialize early-stage technologies. 
    • 
 	
  • Experience in technology development and initial IP landscape review and strategy development.
    • 
 	
  • Experience in the grant application review and the management of approved grants, including the identification and achievement of milestones that have material commercial value.
    • 


Progress Reports

Progress reports detailing meetings held/attended, project development issues, priorities, and other issues of importance are required on a monthly basis. 

Time Commitment

    
 	
  • No less than one full day per week.
    • 
 	
  • Must be available to meet onsite and in-person with CFB staff and clients as needed and required by the CFB.
    • 
 	
  • Ability to respond to urgent requests and to fill in as needed is desirable.
    • 


Proposal Deadline
 The CFB seeks proposals from qualified providers who have the expertise and desire to support the technology and business development objectives of the CFB. Interested parties should submit a proposal of no more than one page to Kristina Duryea at Kristina.Duryea@stonybrook.edu by 5p, May 26, 2017.
                    [post_title] => Request for Proposals: Technology & Business Development Services
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => request-for-proposals-technology-business-development-services
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2017-05-08 17:15:49
                    [post_modified_gmt] => 2017-05-08 17:15:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://centerforbiotechnology.org/?p=2689
                    [menu_order] => 147
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [post_count] => 4
    [current_post] => -1
    [before_loop] => 1
    [in_the_loop] => 
    [post] => WP_Post Object
        (
            [ID] => 5065
            [post_author] => 4
            [post_date] => 2026-09-01 14:03:32
            [post_date_gmt] => 2026-09-01 18:03:32
            [post_content] => 

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.





BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.





Application deadline: October 29, 2026, 5:00pm ET





For info sessions, eligibility and deadlines visit our REACH Website and FAQ.





The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.





Questions? Reach out to our program contacts or sign up for office hours:





Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here





Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here












            [post_title] => BioREACH: Translational Research Funding Opportunity
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => bioreach-translational-research-funding-opportunity
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2026-09-04 11:55:36
            [post_modified_gmt] => 2026-09-04 15:55:36
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://centerforbiotechnology.org/?p=5065
            [menu_order] => 0
            [post_type] => post
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [comment_count] => 0
    [current_comment] => -1
    [found_posts] => 288
    [max_num_pages] => 96
    [max_num_comment_pages] => 0
    [is_single] => 
    [is_preview] => 
    [is_page] => 
    [is_archive] => 
    [is_date] => 
    [is_year] => 
    [is_month] => 
    [is_day] => 
    [is_time] => 
    [is_author] => 
    [is_category] => 
    [is_tag] => 
    [is_tax] => 
    [is_search] => 
    [is_feed] => 
    [is_comment_feed] => 
    [is_trackback] => 
    [is_home] => 1
    [is_privacy_policy] => 
    [is_404] => 
    [is_embed] => 
    [is_paged] => 
    [is_admin] => 
    [is_attachment] => 
    [is_singular] => 
    [is_robots] => 
    [is_favicon] => 
    [is_posts_page] => 
    [is_post_type_archive] => 
    [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
    [query_vars_changed:WP_Query:private] => 
    [thumbnails_cached] => 
    [allow_query_attachment_by_filename:protected] => 
    [stopwords:WP_Query:private] => 
    [compat_fields:WP_Query:private] => Array
        (
            [0] => query_vars_hash
            [1] => query_vars_changed
        )

    [compat_methods:WP_Query:private] => Array
        (
            [0] => init_query_flags
            [1] => parse_tax_query
        )

    [query_cache_key:WP_Query:private] => 
)

BioREACH: Translational Research Funding Opportunity

September 1, 2026

More Information

Dr. Carol A. Carter Elected to U.S. National Academy of Sciences

May 31, 2024

More Information

COVID-19 Funding and Resource Opportunities

May 5, 2020

More Information

Request for Proposals: Technology & Business Development Services

May 8, 2017

More Information